Cerus Corp (CERS) 6.29 $CERS
Cerus Announces Agreement with BARDA for Potential Funding of up to Approximately $180 Million to Advance Its INTERCEPT Red Blood Cell Program
BusinessWire - Sun Jun 19, 3:00PM CDT
Cerus Corporation (NASDAQ: CERS), a biomedical products company focused on improving blood transfusion safety, today announced an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, to support Cerus' clinical development program for pathogen reduction of red blood cell (RBC) components, including access to funding that could support various activities, including funding studies necessary to support an FDA submission and accelerate commercial scale up to facilitate potential adoption by U.S. blood centers.
CERS: 6.29 (+0.20)
Showpad Helps Cerus Corporation Share Vital Information During Zika Epidemic
PR Newswire Europe - Wed Jun 01, 1:30AM CDT
Showpad, the leading sales enablement platform that guides reps to results, today announced that its customer Cerus Corporation, a biomedical company focused in the field of blood transfusion safety, is using Showpad to help educate its blood center customers about ways to maintain the safety of the blood supply during a Zika epidemic. Cerus is able to leverage the Showpad platform quickly and efficiently to share vital medical information with its field sales organization.
CERS: 6.29 (+0.20)
How Well are These Healthcare Stocks Performing? - Radius Health, Cerus, Arrowhead Pharma, and Five Prime Therapeutics
PR Newswire - Thu May 26, 7:50AM CDT
Despite the volatility that continues to envelop the Biotech industry, investors see value in this space. Today's pre-market research on ActiveWallSt.com directs the investor community's focus on the following Healthcare equities: Radius Health Inc. (NASDAQ: RDUS), Cerus Corp. (NASDAQ: CERS), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Five Prime Therapeutics Inc. (NASDAQ: FPRX). Register with us today for these stock technical briefings at:
CERS: 6.29 (+0.20), RDUS: 37.24 (+1.57), ARWR: 5.88 (+0.20), FPRX: 40.78 (+1.13)
Health Canada Approves INTERCEPT Blood System for Plasma
BusinessWire - Mon May 23, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) today announced that Health Canada has approved the INTERCEPT Blood System for plasma. The INTERCEPT Blood System for plasma is intended to be used for the ex vivo preparation of pathogen-reduced, whole blood derived or apheresis plasma in order to reduce the risk of transfusion-transmitted infection (TTI).
CERS: 6.29 (+0.20)
Cerus reports 1Q loss
Automated Insights - Tue May 03, 3:37PM CDT
CONCORD, Calif. (AP) _ Cerus Corp. (CERS) on Tuesday reported a loss of $16.9 million in its first quarter.
CERS: 6.29 (+0.20)
Cerus Corporation Reports First Quarter 2016 Results
BusinessWire - Tue May 03, 3:01PM CDT
Cerus Corporation (NASDAQ:CERS) today announced financial results for the first quarter ended March 31, 2016.
CERS: 6.29 (+0.20)
Cerus Announces that the Walter Reed National Military Medical Center Has Entered Into Routine Use of the INTERCEPT Blood System
BusinessWire - Tue May 03, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS), a biomedical products company focused in the field of blood transfusion safety, announced today that the Walter Reed National Military Medical Center (Walter Reed), a component of the Armed Services Blood Program, has begun routine use of the INTERCEPT Blood System for apheresis platelets. Walter Reed transfuses approximately 1,000 apheresis platelet units annually.
CERS: 6.29 (+0.20)
Cerus to Release First Quarter 2016 Results on May 3, 2016
BusinessWire - Tue Apr 19, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that its first quarter results will be released on Tuesday, May 3, 2016, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook.
CERS: 6.29 (+0.20)
The Race to Cure the Zika Virus is On, and This Company May Have the Best Solution
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 16, 1:18PM CDT
The Aedes aegypti mosquito has become public enemy No. 1. Image source: Centers for Disease Control and Prevention. The Zika virus has been around for decades, but its prevalence has exploded since 2014. The virus itself, which is spread by the...
CERS: 6.29 (+0.20), INO: 9.85 (-0.35), MRK: 57.68 (+0.64), NLNK: 11.24 (+0.59), XON: 25.20 (+0.55), GSK: 42.56 (+0.80), SNY: 41.19 (+0.90)
Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma
BusinessWire - Wed Mar 16, 7:30AM CDT
Cerus Corporation (NASDAQ: CERS), a biomedical products company focused on improving blood transfusion safety, today announced U.S. Food and Drug Administration (FDA) approval of the INTERCEPT Blood System for treatment of platelets suspended in 100% plasma. This extended label claim further enhances compatibility with commonly used platelet collection methods.
CERS: 6.29 (+0.20)
Cerus Announces the Inclusion of Pathogen Reduction Technology in FDA's Revised Guidance Document on Bacterial Safety Standards for Platelets
BusinessWire - Tue Mar 15, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that the U.S. Food and Drug Administration (FDA) has issued a revised draft guidance document titled "Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion; Draft Guidance for Industry." The document is intended to provide blood centers with recommendations for controlling the risk of bacterial contamination of platelets, and pathogen reduction technology is included as a recommended method to reduce the risk of transfusion-transmitted sepsis.
CERS: 6.29 (+0.20)
Covered Call Alerts For Kinder Morgan, Himax Technologies Inc, US Steel, Yahoo! and CERUS Corporation Released By InvestorsObserver
PR Newswire - Thu Mar 10, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for KMI, HIMX, X, YHOO and CERS.
CERS: 6.29 (+0.20), KMI: 18.90 (+0.39), YHOO: 37.78 (+0.42), HIMX: 9.35 (+0.02), X: 18.04 (+0.92)
Blood Centers of America Selects Cerus as its Supply Partner for Pathogen Reduction Technology
BusinessWire - Wed Mar 09, 7:00AM CST
Cerus Corporation (NASDAQ: CERS) and Blood Centers of America (BCA) announced today that they have entered into an agreement with Cerus as a BCA preferred supplier.
CERS: 6.29 (+0.20)
Cerus Corporation Reports Fourth Quarter and Year End 2015 Results
BusinessWire - Tue Mar 08, 3:01PM CST
Cerus Corporation (NASDAQ:CERS) today announced financial results for the fourth quarter and year ended December 31, 2015.
CERS: 6.29 (+0.20)
Cerus Enters Into Agreement With Banco de Sangre de Servicios Mutuos for the Use of INTERCEPT Platelets and Plasma in Puerto Rico to Sustain Blood Supply During Zika Epidemic
BusinessWire - Thu Mar 03, 7:30AM CST
Cerus Corporation (NASDAQ: CERS), a biomedical products company focused on improving blood transfusion safety, today announced that Banco de Sangre de Servicios Mutuos in Puerto Rico has signed a purchase agreement for the INTERCEPT Blood System for platelets and plasma to help protect the local blood supply during the Zika outbreak.
CERS: 6.29 (+0.20)
Covered Call Alerts For Bank of America, CERUS Corporation, Seadrill, Johnson & Johnson and Facebook Released By InvestorsObserver
PR Newswire - Wed Feb 10, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for BAC, CERS, SDRL, JNJ and FB.
CERS: 6.29 (+0.20), JNJ: 117.38 (+0.92), FB: 115.08 (+1.17), BAC: 14.04 (+0.43), SDRL: 3.41 (+0.03)
Cerus Enters Multi-Year Agreement with the American Red Cross for the Use of INTERCEPT Platelets and Plasma
BusinessWire - Tue Feb 09, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that the American Red Cross has signed a multi-year purchase agreement for the INTERCEPT Blood System for platelets and plasma, which inactivates a broad spectrum of viruses, gram-positive and gram-negative bacteria, spirochetes, parasites and leukocytes and is intended to reduce the risk of transfusion-transmitted infection (TTI) in platelet and plasma components.
CERS: 6.29 (+0.20)
Cerus Announces Agreement with BARDA for Potential Funding of up to Approximately $180 Million to Advance Its INTERCEPT Red Blood Cell Program
BusinessWire - Sun Jun 19, 3:00PM CDT
Cerus Corporation (NASDAQ: CERS), a biomedical products company focused on improving blood transfusion safety, today announced an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, to support Cerus' clinical development program for pathogen reduction of red blood cell (RBC) components, including access to funding that could support various activities, including funding studies necessary to support an FDA submission and accelerate commercial scale up to facilitate potential adoption by U.S. blood centers.
CERS: 6.29 (+0.20)
Showpad Helps Cerus Corporation Share Vital Information During Zika Epidemic
PR Newswire Europe - Wed Jun 01, 1:30AM CDT
Showpad, the leading sales enablement platform that guides reps to results, today announced that its customer Cerus Corporation, a biomedical company focused in the field of blood transfusion safety, is using Showpad to help educate its blood center customers about ways to maintain the safety of the blood supply during a Zika epidemic. Cerus is able to leverage the Showpad platform quickly and efficiently to share vital medical information with its field sales organization.
CERS: 6.29 (+0.20)
How Well are These Healthcare Stocks Performing? - Radius Health, Cerus, Arrowhead Pharma, and Five Prime Therapeutics
PR Newswire - Thu May 26, 7:50AM CDT
Despite the volatility that continues to envelop the Biotech industry, investors see value in this space. Today's pre-market research on ActiveWallSt.com directs the investor community's focus on the following Healthcare equities: Radius Health Inc. (NASDAQ: RDUS), Cerus Corp. (NASDAQ: CERS), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Five Prime Therapeutics Inc. (NASDAQ: FPRX). Register with us today for these stock technical briefings at:
CERS: 6.29 (+0.20), RDUS: 37.24 (+1.57), ARWR: 5.88 (+0.20), FPRX: 40.78 (+1.13)
Health Canada Approves INTERCEPT Blood System for Plasma
BusinessWire - Mon May 23, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) today announced that Health Canada has approved the INTERCEPT Blood System for plasma. The INTERCEPT Blood System for plasma is intended to be used for the ex vivo preparation of pathogen-reduced, whole blood derived or apheresis plasma in order to reduce the risk of transfusion-transmitted infection (TTI).
CERS: 6.29 (+0.20)
Cerus reports 1Q loss
Automated Insights - Tue May 03, 3:37PM CDT
CONCORD, Calif. (AP) _ Cerus Corp. (CERS) on Tuesday reported a loss of $16.9 million in its first quarter.
CERS: 6.29 (+0.20)
Cerus Corporation Reports First Quarter 2016 Results
BusinessWire - Tue May 03, 3:01PM CDT
Cerus Corporation (NASDAQ:CERS) today announced financial results for the first quarter ended March 31, 2016.
CERS: 6.29 (+0.20)
Cerus Announces that the Walter Reed National Military Medical Center Has Entered Into Routine Use of the INTERCEPT Blood System
BusinessWire - Tue May 03, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS), a biomedical products company focused in the field of blood transfusion safety, announced today that the Walter Reed National Military Medical Center (Walter Reed), a component of the Armed Services Blood Program, has begun routine use of the INTERCEPT Blood System for apheresis platelets. Walter Reed transfuses approximately 1,000 apheresis platelet units annually.
CERS: 6.29 (+0.20)
Cerus to Release First Quarter 2016 Results on May 3, 2016
BusinessWire - Tue Apr 19, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that its first quarter results will be released on Tuesday, May 3, 2016, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook.
CERS: 6.29 (+0.20)
The Race to Cure the Zika Virus is On, and This Company May Have the Best Solution
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 16, 1:18PM CDT
The Aedes aegypti mosquito has become public enemy No. 1. Image source: Centers for Disease Control and Prevention. The Zika virus has been around for decades, but its prevalence has exploded since 2014. The virus itself, which is spread by the...
CERS: 6.29 (+0.20), INO: 9.85 (-0.35), MRK: 57.68 (+0.64), NLNK: 11.24 (+0.59), XON: 25.20 (+0.55), GSK: 42.56 (+0.80), SNY: 41.19 (+0.90)
Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma
BusinessWire - Wed Mar 16, 7:30AM CDT
Cerus Corporation (NASDAQ: CERS), a biomedical products company focused on improving blood transfusion safety, today announced U.S. Food and Drug Administration (FDA) approval of the INTERCEPT Blood System for treatment of platelets suspended in 100% plasma. This extended label claim further enhances compatibility with commonly used platelet collection methods.
CERS: 6.29 (+0.20)
Cerus Announces the Inclusion of Pathogen Reduction Technology in FDA's Revised Guidance Document on Bacterial Safety Standards for Platelets
BusinessWire - Tue Mar 15, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that the U.S. Food and Drug Administration (FDA) has issued a revised draft guidance document titled "Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion; Draft Guidance for Industry." The document is intended to provide blood centers with recommendations for controlling the risk of bacterial contamination of platelets, and pathogen reduction technology is included as a recommended method to reduce the risk of transfusion-transmitted sepsis.
CERS: 6.29 (+0.20)
Covered Call Alerts For Kinder Morgan, Himax Technologies Inc, US Steel, Yahoo! and CERUS Corporation Released By InvestorsObserver
PR Newswire - Thu Mar 10, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for KMI, HIMX, X, YHOO and CERS.
CERS: 6.29 (+0.20), KMI: 18.90 (+0.39), YHOO: 37.78 (+0.42), HIMX: 9.35 (+0.02), X: 18.04 (+0.92)
Blood Centers of America Selects Cerus as its Supply Partner for Pathogen Reduction Technology
BusinessWire - Wed Mar 09, 7:00AM CST
Cerus Corporation (NASDAQ: CERS) and Blood Centers of America (BCA) announced today that they have entered into an agreement with Cerus as a BCA preferred supplier.
CERS: 6.29 (+0.20)
Cerus Corporation Reports Fourth Quarter and Year End 2015 Results
BusinessWire - Tue Mar 08, 3:01PM CST
Cerus Corporation (NASDAQ:CERS) today announced financial results for the fourth quarter and year ended December 31, 2015.
CERS: 6.29 (+0.20)
Cerus Enters Into Agreement With Banco de Sangre de Servicios Mutuos for the Use of INTERCEPT Platelets and Plasma in Puerto Rico to Sustain Blood Supply During Zika Epidemic
BusinessWire - Thu Mar 03, 7:30AM CST
Cerus Corporation (NASDAQ: CERS), a biomedical products company focused on improving blood transfusion safety, today announced that Banco de Sangre de Servicios Mutuos in Puerto Rico has signed a purchase agreement for the INTERCEPT Blood System for platelets and plasma to help protect the local blood supply during the Zika outbreak.
CERS: 6.29 (+0.20)
Covered Call Alerts For Bank of America, CERUS Corporation, Seadrill, Johnson & Johnson and Facebook Released By InvestorsObserver
PR Newswire - Wed Feb 10, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for BAC, CERS, SDRL, JNJ and FB.
CERS: 6.29 (+0.20), JNJ: 117.38 (+0.92), FB: 115.08 (+1.17), BAC: 14.04 (+0.43), SDRL: 3.41 (+0.03)
Cerus Enters Multi-Year Agreement with the American Red Cross for the Use of INTERCEPT Platelets and Plasma
BusinessWire - Tue Feb 09, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that the American Red Cross has signed a multi-year purchase agreement for the INTERCEPT Blood System for platelets and plasma, which inactivates a broad spectrum of viruses, gram-positive and gram-negative bacteria, spirochetes, parasites and leukocytes and is intended to reduce the risk of transfusion-transmitted infection (TTI) in platelet and plasma components.
CERS: 6.29 (+0.20)
